Opthea Company Description

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States.

The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).

It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.

Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Opthea Limited

Country	Australia
Founded	1984
Industry	Biotechnology
Sector	Healthcare
Employees	33
CEO	Jeremy Levin

Contact Details

Address: Level 9 Melbourne, 3000 Australia
Phone	61 3 9826 0399
Website	opthea.com

Stock Details

Ticker Symbol	OPT
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	USD
ISIN Number	AU000000OPT2
SIC Code	2836

Key Executives

Name	Position
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.	Chief Executive Officer and Chairperson